Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Frequently asked questions
What sector does CRYO-CELL INTL DL-01 (ZCY) operate in?
CRYO-CELL INTL DL-01 belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is CRYO-CELL INTL DL-01 (ZCY) current stock price?
As of the latest data, CRYO-CELL INTL DL-01 stock price is €3.72, with a previous close of €3.70. CRYO-CELL INTL DL-01 gained €0.02 in the last trading session, representing a 0.54% increase.
What is CRYO-CELL INTL DL-01 (ZCY) current market capitalization?
CRYO-CELL INTL DL-01 market cap is approximately 29.99 million.
What is CRYO-CELL INTL DL-01 (ZCY) Earnings Per Share (EPS)?
The trailing EPS is -€0.21.
What is CRYO-CELL INTL DL-01 (ZCY) EBITDA?
CRYO-CELL INTL DL-01 EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 1.38 million.
Does CRYO-CELL INTL DL-01 (ZCY) pay dividends?
No. CRYO-CELL INTL DL-01 does not pay a dividend.
What is CRYO-CELL INTL DL-01 (ZCY) beta (volatility) score?
CRYO-CELL INTL DL-01 has a beta of 0.590, indicating lower volatility than the overall market.
